INTRODUCTION
============

The 26S proteasome is a large multi-protein complex and plays a central role in ubiquitin-dependent proteolysis in eukaryotic cell. The 20S core proteasome (CP; ∼700 kDa) and the 19S regulatory proteasome (RP; ∼900 kDa) interact to form the 26S proteasome. Association of the 19S RP with either one or both ends of the 20S CP results in the formation of the 26S (RP~1~-CP) and 30S (RP~2~-CP), respectively. The term "26S proteasome" is commonly used to refer to both isoforms, as the RP~2~-CP, RP~1~-CP, and CP, as well as various assembly intermediates, all coexist in the cell (1). In rat cortex, RP~2~-CP comprises approximately 14% of the proteasome complement, whereas RP~1~-CP comprises approximately 43% (2). Instead of the 19S RP, the 26S proteasome can includes various ATP-independent regulatory molecules, such as PA28α/β, PA28γ, PA200, PI31, PC530, or the signalosome COP9 (1). These alternative regulatory molecules also associate with the ends of the 20S CP, potentially resulting in the formation of asymmetric 26S proteasome isoforms. Although they lack ATPase activity, the alternative regulatory molecules mediate ubiquitin-independent protein degradation. The subunits of the 26S proteasome are listed in [Table 1](#T001){ref-type="table"}.

###### Subunits of the 26S proteasome

  -------- -------- ------------ ------------------------------- --------------------------- --------------------------------------------------- ------------------
                    Subunit      S. cerevisiae                   Mammals                     Activity/Function                                   Size\*\* (human)
                                                                                                                                                 
  20S CP   α ring   α1           Scl1/Prc2/Prs2/C7               PSMA6/Pros27/Iota                                                               27.4
                    α2           Pre8/Prs4/Y7                    PSMA2/C3/Lmpc3                                                                  25.8
                    α3           Pre9/Prs5/Y13                   PSMA4/C9                    Gate opening                                        29.4
                    α4           Pre6                            PSMA7/C7/XAPC7                                                                  27.9
                    α5           Pup2/Doa5                       PSMA5/Zeta                                                                      26.5
                    α6           Pre5                            PSMA1/C2/Pros30                                                                 29.6/30.1^\#^
                    α7           Pre10/Prc1/Prs1/C1              PSMA3/C8                                                                        28.3
           β ring   β1           Pre3                            PSMB6/Y/delta/LMPY/LMP19    PGPH\* activity                                     
                    β1i                                          PSMB9/Lmp2/RING12/MC7       Chymotrypsin-like activity                          
                    β2           Pup1                            PSMB7/Z/MC14/Lmp9           Trypsin-like activity                               25.3
                    β2i                                          PSMB10/MECL-1/Lmp10         Trypsin-like activity                               
                    β3           Pup3                            PSMB3/C10                                                                       22.9
                    β4           Pre1/C11                        PSMB2/C7                                                                        22.8
                    β5           Pre2/Doa3/Prg1                  PSMB5/X/epsilon/MB1/Lmp17   Chymotrypsin-like activity                          22.5
                    β5i                                          PSMB8/Lmp7/RING10/Y2/C13    Chymotrypsin-like activity                          
                    β6           Pre7/Prs3/Pts1/C5               PSMB1/C5                                                                        23.5
                    β7           Pre4                            PSMB4/N3/beta/LMP3                                                              24.4
  19S RP   Base     Rpt1/S7      Rpt1/Cim5/Yta3                  PSMC2/Mss1                  AAA ATPase                                          48.6
                    Rpt2/S4      Rpt2/Yhs4/Yta5                  PSMC1                       AAA ATPase / Gate opening                           49.2
                    Rpt3/S6b     Rpt3/Ynt1/Yta2                  PSMC4/Mip224/Tbp7           AAA ATPase                                          47.3
                    Rpt4/S10b    Rpt4/Crl13/Pcs1/Sug2            PSMC6/Sug2/p42              AAA ATPase                                          44.1
                    Rpt5/S6a     Rpt5/Yta1                       PSMC3/Tbp1                  AAA ATPase / Ub receptor / Gate opening             49.1
                    Rpt6/S8      Rpt6/Cim3/Crl3/Sug1/TbpY/Tby1   PSMC5/p45/Sug1/Trip1        AAA ATPase                                          45.7
                    Rpn1/S2      Rpn1/Hrd2/Nas1/Rpd1             PSMD2/p97/Trap2             Ub receptor / Binding of substrate / Gate opening   100.2
                    Rpn2/S1      Rpn2/Sen3                       PSMD1/p112                  Ub receptor / Binding of substrate / Gate opening   105.9
                    Rpn10/S5a    Rpn10/Sun1/Mcb1                 PSMD4/S5a/Mcb1              Ub receptor / Interface of lid & base               40.7
                    S5b          \-                              PSMD5/KIAA0072                                                                  
                    Rpn13        Rpn13/Daq1                      ADRM1                       Ub receptor                                         42.1
           Lid      Rpn3/S3      Rpn3/Sun2                       PSMD3/p58                                                                       61.0
                    Rpn4         Rpn4/Son1/Ufd5                  \-                                                                              
                    Rpn5/p55     Rpn5/Nas5                       PSMD12/p55                                                                      52.9
                    Rpn6/S9      Rpn6/Nas4                       PSMD11/p44.5                Binding of substrate (possible)                     47.4
                    Rpn7/S10     Rpn7                            PSMD6/p42a                                                                      45.5
                    Rpn8/S12     Rpn8                            PSMD7/p40/Mov34                                                                 37.1
                    Rpn9/Nas7    Rpn9/Nas7                       PSMD13/p40.5                                                                    42.9
                    Rpn11/S13    Rpn11/Mpr1                      PSMD14/Pad1/Poh1            Deubiquitinase                                      34.6
                    Rpn12/S14    Rpn12/Nin1                      PSMD8/p31                                                                       30.0
                    Rpn15/Sem1   Rpn15/Sem1/Dsh1                 SHFM1/DSS1/SHFDG1                                                               24.6
                    p27          Nas2                            PSMD9/p27                                                                       
                    p28          Nas6                            PSMD10/p28/Gankyrin                                                             
  -------- -------- ------------ ------------------------------- --------------------------- --------------------------------------------------- ------------------

\*PGPH: peptidylglutamyl-peptide hydrolyzing (also called caspase-like activity). \*\*Unit of size: kDa. ^\#^Long and short isoform of the α6 subunit

20S CP
------

The eukaryotic 20S CP has a cylindrical structure consisting of four hetero-heptameric rings, two outer and two central. The two outer rings are composed of seven α-subunits (α1-α7) and the two central rings are composed of seven β-subunits (β1-β7) [@B003]. Mammalian cells also contain immunoproteasomes that can be activated by treatment with interferon-γ (IFNγ), which stimulates the synthesis of three additional proteasome subunits: β1i, β2i, and β5i. The immune-20S CP (i-CP) is then formed by the substitution of β1, β2, and β5 with β1i, β2i, and β5i, respectively [@B004].

**Catalytic activity of the 20S CP:** Of the seven β-subunits, only three (β1, β2, and β5) exhibit threonine protease hydrolytic activity [@B003]. These subunits cleave a different peptide sequence; for example, β1 hydrolyzes on the C-terminal side after acidic residues, β2 hydrolyzes on the C-terminal side after tryptic residues, and β5 hydrolyzes on the C-terminal side after hydrophobic residues. Subunits β1, β2, and β5 are referred to as exhibiting peptidylglutamyl-peptide hydrolyzing activity (PGPH; also called caspase-like activity), tryptic activity, and chymotryptic activity, respectively. The protease activity of subunits β1, β2, and β5 is self-activated via a two-step mechanism characterized by initial reduction of the length of the propeptide sequence and subsequent autocatalytic removal of the residual propeptide.

**RNase activity:** The 20S CP (particularly the α5 subunit) exhibits RNase activity dependent upon divalent cations such as Ca^2＋^ and Mg^2＋^, whereas the proteolytic activity does not require divalent cations [@B005]. Interestingly, the α5-RNase activity is highly correlated with the extent of α6- and α7-subunit phosphorylation. Moreover, the α5-RNase activity increases markedly during erythroid differentiation and programmed cell death [@B005]. Mittenberg *et al.* recently reported that most α-subunits (except α3) exhibit *in vitro* RNase activity against *p53* mRNA [@B006]. They also reported that the RNase activity of the α6- and α7-subunit is upregulated upon hemin-induced differentiation of proerythroleukemia cells, in parallel with changes in their phosphorylation and ubiquitination status [@B006].

19S RP
------

The 19S RP consists of base and lid complexes and functions as an ATP-dependent proteasome activator. The base complex comprises six AAA^＋^-ATPase subunits (regulatory particle triple A-ATPase 1 \[Rpt1\]-Rpt6) and three non-ATPases ([r]{.ul}egulatory [p]{.ul}article [n]{.ul}on-ATPase 1 \[Rpn1\], Rpn2, and Rpn10) [@B001]. In mammals, the base complex also contains hRpn13 and S5b, whereas that of *Saccharomyces cerevisiae* contains Rpn13 [@B007]. The six Rpt subunits form a heterohexameric ring in which the Rpn1 and Rpn2 are stacked [@B001]. The lid complex comprises eight non-ATPases (Rpn3, 5-9, 11, and 12) [@B001]. The lid is loosely (i.e., temporarily) associated with other subunits, such as p27, p28, and Rpn15, and in *S. cerevisiae*, the lid is also associated with Rpn4. Interaction between the base and the lid complex is stabilized by Rpn10 [@B001].

Functions of the 19S RP
-----------------------

The 19S RP interacts with the 20S CP to trigger opening of the gate in the 20S CP through conformational rearrangement of the N-terminal region of the α-subunit [@B008]. Base complex subunits Rpt2, Rpt5, Rpn1, and Rpn2 participate in the gate-opening process [@B009]. Rpn10 then captures polyubiquitinated substrates via the C-terminal hydrophobic cluster. Whereas isolated Rpn10 protein interacts with three forms of polyubiquitin (Lys6, Lys11, or Lys 48) in equal ratios, the intact 26S proteasome interacts only with Lys48-linked polyubiquitin chains [@B010]. Rpn1, Rpn2, Rpn13, and Rpt5 are also involved in capturing of polyubiquitinated substrates. Rpn1 and Rpn2 contain a leucine-rich repeat domain that is involved in non-specific protein-protein interactions and also plays an important role in substrate binding [@B011]. The previously reported finding that ubiquitinated nuclear factor κB/p100 interacts with Rpn6 [@B012] suggests that Rpn6 is another proteasome substrate acceptor. Multiple Rpt subunits also interact with substrates. Before translocation into the 20S CP, substrates are fully unfolded by the 19S RP, utilizing energy derived from the hydrolysis of ATP [@B013]. The lid subsequently releases the polyubiquitin chain from the substrates to facilitate their degradation, in which Rpn11 plays a role [@B014].

Alternative ATP-independent regulatory particles
------------------------------------------------

**PA28 (also called 11S regulator):** The PA28 family consist of PA28α/β and PA28γ. PA28α/β has a heteroheptameric ringshaped structure and is composed of either an α4β3 or α3β4 complex [@B015]. PA28α/β associates with the two ends of the 20S CP or the free end of asymmetric 19S-20S CPs to form 19S-20S-PA28. PA28 accelerates the degradation of small peptides, but it has no effect on the degradation of folded or ubiquitinated proteins [@B015]. The PA28 α- and β-subunits promote proteasome activity and contain a highly conserved linker sequence between helices 2 and 3, which is referred as "the activation loop", a structure that is important for the activity-stimulating effect of PA28 [@B015]. Expression of PA28α/β is induced by IFNγ. Under conditions that induce an intensified immune response, PA28α/β associates tightly with the i-CP. In contrast to PA28α/β, IFNγ does not induce expression of the PA28γ subunit. In addition, the PA28γ subunit forms homoheptamers and associates with the 20S CP, activating primarily the tryptic activity [@B016].

**PA200 (also called Blm10 or Blm3):** PA200 is a monomeric protein with an asymmetric turban-like shape. PA200 attaches to one or both ends of the 20S CP to induce the hydrolysis of small peptides (but not folded proteins) *in vitro*, but the induction only of peptide hydrolysis is not seen with the yeast homologue, Blm10 [@B017]. PA200 connects the 26S proteasome to the proteins that recognize regions of DNA molecules damaged by ionizing radiation [@B018]. Once recruited to the region of damaged DNA, the 26S proteasome degrades the chromatin-associated proteins there to expose the damaged section of DNA for repair enzymes [@B018].

**PI31:** PI31 is a proline-rich protein that competes with other regulatory proteins for binding to the 20S CP. *In vitro*, PI31 forms an unstable complex with the 20S CP [@B001] and inhibits the chymotryptic and PGPH activity while stimulating the tryptic activity of the 20S CP. PI31 also plays a role in immunoproteasome biogenesis, instead of the usual ATP/ ubiquitin-dependent protein degradation [@B015].

**PC530:** PC530 is a multi-protein complex originally identified in starfish oocytes. PC530 associates with the 20S CP to regulate the removal of defective sperm in the epididymis and paternal mitochondria in fertilized eggs [@B019].

**The COP9 Signalosome (CSN):** The CSN consists of eight subunits (CSN1-8) that are highly homologous to the subunits of the 19S RP lid. The CSN replaces and assumes the function of the 19S RP lid in the 26S proteasome [@B001]. The CSN also exhibits de-ubiquitination activity [@B020].

REGULATION AND UNDERLYING MOLECULAR MECHANISMS OF PROTEASOME ASSEMBLY AND PROTEOLYSIS
=====================================================================================

Regulation of 26S proteasome assembly and novel modulators
----------------------------------------------------------

Considering the biological importance of the 26S proteasome, its assembly would be expected to proceed in a precise and tightly controlled manner. The process of 26S proteasome assembly is complex, however, as 66 proteins must be assembled into a functional complex in an exact order. In addition, some proteasome subunits must be processed during assembly. Previous studies revealed that several chaperone proteins actively mediate assembly of the highly complex proteasome in an extremely efficient and accurate process. A schematic illustration of the pathway for assembly of the entire 26S proteasome based on currently available data is shown in [Fig. 1](#F001){ref-type="fig"}.

![Schematic diagram illustrating assembly of the 26S proteasome.](BMB-49-459-g001){#F001}

Assembly of the 20S CP
----------------------

**Archaeal CP:** Each α- and β-subunit of the archaeal CP is encoded by a single-copy gene. Binding between subunits results in the formation of a homoheptameric ring [@B021]. The α-subunit alone can form single or coupled heptameric rings via its N-terminal α-helix. In contrast, the β-subunit cannot self-assemble into multimeric structures and remains in the monomer state. Proteolytic cleavage of the β-subunit leads to the formation of inactive rings [@B021]. Assembly of the archaeal CP is probably initiated by formation of the α-ring, which then attaches to the β-subunit to form a half-proteasome. Two half-proteasomes assemble into the pre-CP, which is finally converted into the mature CP after cleavage of the N-terminal propeptide of the β-subunit [@B021]. Panfair *et al.* [@B022] proposed three plausible 20S CP assembly pathways: (a) α-subunits self-assemble *in cis* to form a single-ring (SR) that serves as a template for β-subunit entry; (b) interaction between multiple α-subunits and a β-subunit, independent of the SR, lead to the formation of the half-proteasome; and (c) α-subunits interacts with each other in trans, resulting in the formation of a double-ring structurally analogous to a half-proteasome.

**Bacterial CP:** The bacterial CP is composed of both α- and β-subunits [@B023]. In contrast to the archaeal CP, bacterial α-subunits do not self-assemble to form a ring structure. In bacteria, one α- and one β-subunit form a heterodimer that assembles into a half-proteasome. Analyses of the crystal structure of a bacterial CP revealed that the β-subunit propeptide acts as an intramolecular chaperone, mediating CP assembly by inserting into the interface between two adjacent α-subunits and acting to hold them together [@B024].

**Eukaryotic CP:** Studying the assembly of the eukaryotic CP is difficult due to the heterogeneity and short half-lives of the ≥33 associated subunits. The involvement of several chaperone proteins adds to the complexity of the eukaryotic CP assembly process. Eukaryotic CP assembly usually involves four steps, as described below: [***Step 1: α-ring formation.***]{.ul} Formation of the α-ring is promoted by several chaperone proteins, including proteasome assembling chaperone 1 (PAC1; also known as proteasome biogenesis-associated-1 \[Pba1\] in yeast)-PAC2 and PAC3-PAC4 heterodimers. The PAC1-PAC2 complex initiates formation of an α-ring intermediate composed of all α-subunits except α3 and α4 [@B021]. The PAC1-PAC2 heterodimer remains attached to the α-ring until the assembly is completed to prevent aberrant dimerization of immature intermediate α-ring [@B025]. Formation of the mature α-ring involves another chaperone, the PAC3-PAC4 heterodimer, which interacts with α5 at a site opposite the site at which PAC1-PAC2 interacts. It is important to promote the appropriate incorporation of α3 and α4 [@B025]. [***Step 2: β-ring formation.***]{.ul} Formation of the β-ring begins with the attachment of β2 to the α-ring, followed by the binding of β3 and β4. The β2 propeptide recruits β3, and then β2 wraps around β3 to initiate formation of the β-ring. Upon β3 incorporation, the PAC3-PAC4 heterodimer dissociates from the α-ring [@B025]. The resulting intermediate, known as the 13S complex, consists of an α-ring, β2-β4, and the PAC1-PAC2 heterodimer. After PAC3-PAC4 dissociation, the β5 propeptide (which is required for β6 recruitment) interacts with underpinning maturation of proteasome 1 (UMP1), which then recruits β6 and β1 to the 13S complex. This process results in the formation of a pre-half-proteasome, also called the 15S precursor complex. Finally, β7 associates with the pre-half-proteasome and triggers the formation of the half-proteasome (also called the 15S complex) [@B025]. Sahara *et al.* [@B026] recently identified two chaperones, transmembrane recognition complex 40 and Bag6. Knockdown of these chaperones leads to accumulation of CP assembly intermediates and inefficient β-subunit assembly on the α-ring. [***Step 3: dimerization of the half-proteasome.***]{.ul} Dimerization of the half-proteasome occurs after incorporation of β7. The extended C-terminal tail of β7 is inserted between β1 and β2 on the opposing β-ring, forming a strong dimer composed of two half-proteasomes and stabilizing the active β1 conformation [@B027]. The β5 propeptide and N-terminal extension of β6 also promote half-proteasome dimerization. In contrast, the β6 propeptide and UMP1 inhibit half-proteasome dimerization. UMP1 in particular functions to inhibit dimerization until all β-subunits are recruited onto the α-ring [@B021]. [***Step 4: maturation.***]{.ul} The dimerized half-proteasome is initially loosely packed, with a wider gate than the mature CP [@B028], but it is then re-arranged by sequential removal of β-propeptides. Finally, the dimerized proteasome degrades UMP1, the PAC1-PAC2 complex is released and recycled for a new round of proteasome assembly, and the gate is tightened [@B028], [@B029].

**CP isoforms:** Eukaryotic cells contain two additional CP isoforms: i-CP and thymo-CP (t-CP). The β-subunits of the i-CP and t-CP differ from those of the 20S CP. The i-CP contains β1i, β2i and β5i instead of β1, β2, and β5, respectively [@B004]. The t-CP contains thymus-specific β5t instead of β5 or β5i [@B030]. β1i is incorporated into the i-CP earlier than β1 and therefore can facilitate the incorporation of β2i. Thus, β1i and β2i are incorporated before the other β-subunits, with subsequent recruitment of β3, β4, β5i (or β5t), and β6. As with the 20S CP, the i-CP and t-CP half-proteasomes dimerize after the incorporated of β7 [@B029]. The same chaperone proteins involved in the assembly of the 20S CP are also involved in the assembly of the i-CP and t-CP.

Assembly of the 19S RP
----------------------

**Base assembly:** As with the CP, assembly of the RP base is tightly orchestrated and regulated by a number of chaperone proteins, including Nas2/p27, Nas6/gankyrin/p28, Rpn14/ PAAF1, Hsm3/S5b, parkin, Bag6, and Adc17, which bind to the C-terminus of specific Rpts to facilitate proper pairing. Two hypothetic models of the base assembly process have been proposed: CP-independent and CP-dependent assembly. [***CP-independent assembly.***]{.ul} CP-independent assembly involves selective interaction of Hsm3 with Rpt1, Nas2 with Rpt5, Nas6 with Rpt3, and Rpn14 with Rpt6 [@B031]. In addition, interaction between Rpt1 and Rpn1 is mediated by parkin (a protein linked to Parkinson disease) [@B032]. Bag6 directly binds to Rpt5 and promotes the interaction between Rpt4 and the Nas2-Rpt5 complex [@B026]. Adc17 interacts with the C-terminus of Rpt6 to facilitate formation of the Rpt6-Rpt3 complex [@B033]. These interactions ultimately lead to the formation of three intermediates, Hsm3-Rpn1-Rpt1-Rpt2, Nas2-Rpt4-Rpt5, and Nas6- Rpt3-Rpt6-Rpn14, which then form a heterohexameric ring with Rpn2, Rpn10, and Rpn13 [@B031]. [***CP-dependent assembly.***]{.ul} In CP-dependent assembly, Rpt4, Rpt6, and possibly Rpt3 interact to form a complex directly on the CP. Rpn14 and Nas6 guide the complex to the appropriate position at which specific α-ring pockets of the CP can interact with the C-terminus of the Rpts. The Hsm3-Rpn1-Rpt1-Rpt2 complex is subsequently formed independent of the CP and recruited and positioned at the Hsm3-Rpn1-Rpt1-Rpt2 complex on the CP [@B034].

**Lid assembly:** Analyses of the intact lid using mass spectrometry (MS) have suggested two possible intermediate complexes; one comprised of Rpn5, Rpn6, Rpn8, Rpn9, and Rpn11, and another comprised of Rpn3, Rpn7, Rpn12, and Rpn15. Subunits Rpn3, Rpn7, Rpn12, and Rpn15 form a helical bundle that directs the ordered self-assembly of C-terminal helices and proteasome COP9 initiation factor 3 domains. These two intermediates are connected by the interaction between Rpn3 and Rpn5 [@B035]. Finally, Rpn12 is incorporated into the lid complex to complete the assembly process [@B036]. Prior to the attachment of Rpn12, this complex exists in a closed state with the N-terminal domain of Rpn6 folded inward, inhibiting binding to the base. During Rpn12 incorporation, the single α-helix of Rpn12 induces the repositioning of Rpn8 and Rpn11 and a conformational change in the N-terminus of Rpn6 that consequently promotes its binding to the base [@B036]. Two chaperones are involved in lid assembly: Hsp90 and Yin6. Inactivation of the proteins or deletion of their gene results in lid disassembly [@B021]. The lid complex is subsequently joined to the base via an interaction between Rpn10 and the helical N-terminal domain of Rpn9 [@B037]. The observation that parkin overexpression markedly enhances the interaction between Rpn6 and Rpt5 suggests that parkin may help stabilize the base and lid complexes [@B032].

RP-CP association
-----------------

Precise regulation of RP-CP association is critical for proper proteasome function because both CP maturation and gate opening require association with the RP. The RP and CP complex is assembled via interaction between the C-terminus of Rpts and α-subunit pockets [@B038]. Tian *et al.* reported that the CP exhibits unexpected asymmetry, in that one side of the ring makes 1:1 contacts between Rpt2 and α4, Rpt6 and α3, and Rpt3 and α2, whereas on the opposite side, the tails of Rpt1, Rpt4 and Rpt5 cross-link with α5/α6, α7/α1, and α6/α7, respectively [@B038]. The Rpt6-α3 interaction promotes both the Rpt3-α2 interaction through ATP-dependent binding with Nas6 and the release of Nas6 from the proteasome [@B039]. Both Ecm29 and Hsp90 have been shown to regulate RP-CP assembly. Purified proteasomes from a bacterial strain lacking the *Ecm29* gene exhibited CP-RP dissociation. Ecm29 stabilizes the 26S proteasome by enhancing the interaction between the RP and CP [@B021]. Loss-of-function mutations in *Hsp90* lead to dissociation of the 26S proteasome [@B021]. However, the mechanism underlying the interaction between the RP and CP remains unclear. Interestingly, we recently found that the telomerase catalytic subunit hTERT exhibits a novel chaperone activity, selectively mediating the association between the RP and CP (Im and Chung, manuscript in preparation). Specifically, hTERT promotes the interactions between RP and CP subunits, thus facilitating proteasome assembly and subsequent proteasome-mediated proteolysis.

Gate opening within the 20S CP
------------------------------

Under resting conditions, 20S CP activity is auto-inhibited by the N-terminus of the α-subunit tail. Fully unfolded proteins are translocated by the RP into the chamber of the 20S CP through a gate formed by the CP tails [@B040]. The first 12 amino acids of the α-subunit block the catalytic sites of the β-subunit [@B008]. The tail of the α-subunit has a conserved 'Tyr8-Asp9-Arg10' (YDR) sequence. All α-subunits have Tyr8, whereas six of the seven α-subunits (except α2) have Asp9, and three of the seven α-subunits (α1, α4, and α5) have Arg10. In α3, the carboxylate group of Asp9 forms a salt bridge with the guanidinium group of Arg10 in α4. It also forms hydrogen bonds with the carboxylated group of α4-Asp9. Deletion of the 9-residue tail (GSRR[YD]{.ul}SRT) of the α3 subunit leads to disordered formation of the other six α-subunits, resulting in opening of the 20S CP gate along the 7-fold pseudo-symmetric axis [@B040]. Substitution of α3-Asp9 with Ala promotes normal gate opening, thus increasing peptide hydrolysis [@B040].

Gate opening can also occur upon binding of the CP to activator proteins, such as the 19S RP, PAN, PA26, and PA200. The ATPases in the 19S RP and PAN complexes contain a conserved C-terminal hydrophobic-tyrosine-X (HbYX) motif. This motif induces ATP-dependent gate opening and is important to the binding of PAN to the 20S CP [@B041]. The C-terminal regions of Rpt2 and Rpt5 contain the HbYX motif and strongly stimulate gate opening, whereas Rpt3, which also contains the HbYX motif, does not appear to stimulate opening. Furthermore, Rpt1, which contains the YX sequence, induces only weak gate opening, whereas Rpt4 and Rpt6, which do not contain the HbYX motif, have no effect [@B041]. The C-terminal domain of PAN inserts into the pockets between the α-subunits, where it interacts with the highly conserved residues Gly34 and Leu81 [@B041]. Through these interactions, HbYX motif of PAN induces a rotation of the α-subunits of about 4° around Gly128, which is a key residue in the highly conserved α-subunit loop (Tyr126-Gly127-Gly128) [@B041].

The rotation of the α-subunit results in radial and lateral movement of Pro17 away from the pore and a reverse-turn interaction between four highly conserved residues (Tyr8, Asp9, Pro17, and Tyr26) that serves to stabilize the open-gate conformation [@B008], [@B041]. Rosenzweig *et al.* also suggested that the Rpn1-Rpn2 interaction plays some role in regulating gate opening via binding of the Rpn1-Rpn2 complex with the 20S CP to facilitate the entry of small substrates [@B009]. PA26, a PA28 homologue from *Trypanosoma brucei*, also induces gate opening via the same mechanism as PAN, although the C-terminal region of PA26 lacks the HbYX motif [@B042]. Unlike PAN, PA26 function requires an activation loop (clustered between Arg141 and Gly149) that induces a reverse turn in the α-subunits that facilitates gate opening and stabilizes the open conformation [@B042]. The C-terminal region of PA200 has a YYX motif (or less frequently, a YFX motif) that is analogous to the C-terminal HbYX motif of PAN and three ATPases. It is thought that this motif could trigger the degradation of proteasome substrates by inducing gate opening [@B043].

Regulation of 26S proteasome activity by post-translational modifications
-------------------------------------------------------------------------

Numerous reports have demonstrated that proteasomal subunits are subject to a diverse array of post-translational modifications (PTMs), including phosphorylation, N-acetylation, ubiquitination, SUMOylation, O-glycosylation, succinylation, poly-ADP ribosylation, oxidation, N-terminal processing, proteolytic cleavage by caspases, and *N*-myristoylation ([Table 2](#T002){ref-type="table"}). As most of these modifications were identified during large-scale proteomics analyses of cells or tissues, the specific roles of many of these PTMs and their targets have yet to be clearly elucidated. Nevertheless, the functional consequences or/and specific roles of PTMs of various enzymes and modulators have been examined.

###### Modifications of 26S proteasome subunits

  ------------ ----------------------- --------------------- ------------------ ----------------- ---------------- ------------- --------------- ----------------- --------------- ----------------------- --------------- ------------------ --------------------- ------- ------- ------- ----------
  Subunit      N-terminal processing   Cleavage by caspase   N-myristoylation   Phosphorylation   Ubiquitination   SUMOylation   N-acetylation   O-Glycosylation   Succinylation   Poly-ADP ribosylation   Carbonylation   HNE modification   S-glutathionylation                           
                                                                                                                                                                                                                                                                                            
  Cas3         Cas7                    SUMO1                 SUMO2              SUMO3             SUMO4                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                            
  α1                                                                                              O (m)            K59 (H)                                                                                 O (y)           S5 (m)                                                   O (r)   
  α2                                                         O (H)                                Y120 (m)         O (H)                                                                                   O (y)           O (m)                                                    O (r)   
  α3                                                                                              S74 (H)                        O (y)           O (H)                                                     O (y)           O (m)              O (y)                                 O (r)   
  α4                                                                                              Y106             K115 (H)                                                                                O (y)           S130 (m)           O (y)                                 O (r)   
                                                                                                  Y153 (H)                                                                                                                                                                                  
  α5                                                                                                                                             O (H)                                                     O (y)           S198                                                     O (r)   C76
                                                                                                                                                                                                                           (H, m)                                                           C11
                                                                                                                                                                                                                                                                                            C221 (y)
  α6                                                         O (H)                                                 K115                                            O (H)                                   O (y)           S110 (m)                                                 O (r)   C66 (y)
                                                                                                                   K208 (H)                                                                                                                                                                 
  α7                                                                                              S243                                                                                                     O (y)                              O (y)                                 O (H)   C42
                                                                                                  S250 (M)                                                                                                                                                                                  C76 (y)
  α-sub-unit                                                                                      T84                                                                                                                                                                                       
                                                                                                  T178                                                                                                                                                                                      
                                                                                                  T202 (b)                                                                                                                                                                                  
  β1           O (y)                                                                                                                                                                                       O (y)                                                                            
  β1i                                                                                                                                                                                                                                                                               O (r)   
  β2           O (y)                                                                              O (m)                                                                                                    O (y)           O (m)                                                            
  β3                                                                                              O (m)                                                                                                    O (y)                              O (y)                                 O (r)   
  β4                                                                                                                                             O (H)                                                                                        O (y)                                 O (r)   
  β5           O (y)                                                                                                                                                                                       O (y)           O (m)                                                            
  β6           O (y)                                                                                                                                                                                                       S57                O (y)                                 O (r)   
                                                                                                                                                                                                                           S208 (m)                                                         
  β7           O (y)                                                                              O (m)                                                                                                                                                                                     
  20S CP                                                                                                                                                                                                                                                            O (H)                   
  Rpt1                                                       O (H)                                                 O (H)                                           O (H)           O (H)                                                                                                    
  Rpt2                                 D288 (m)                                 O (H, m, y)                        K237 (H)                                                                                                O (H)                                                            
  Rpt3                                                                                            T25 (m)                                                                                                  O (y)                              O (y)                         O (H)           
  Rpt4                                                                                                                                                                                                     O (y)                                                                            
  Rpt5                                 D27 (H)                                                    O (H, m)                                                                                                 O (y)                                                            O (H)           
  Rpt6                                 D248 (m)                                                   S120 (r)                                                                         O (H)                   O (y)                              O (y)                                         
  Rpn1                                                                                                                           O (y)           O (H)                                                                                                                                      O (H)
  Rpn2                                 D85 (H)                                                                                                   O (H)                                                     O (y)                              O (y)                                         O (H)
  Rpn10        D11 D258 (H)                                  K71^\#^            O (H)             O (H)            O (H)                                                                                                                                                                    
                                                             K84^\#^                                                                                                                                                                                                                        
                                                             K99^\#^                                                                                                                                                                                                                        
                                                             K112                                                                                                                                                                                                                           
                                                             K126                                                                                                                                                                                                                           
                                                             K135                                                                                                                                                                                                                           
                                                             K262                                                                                                                                                                                                                           
                                                             K268^\#^                                                                                                                                                                                                                       
                                                             K365 (H)                                                                                                                                                                                                                       
  Rpn13                                                      O (y)                                                                               O (y)                                                                                                                                      
  Rpn3                                                                                                                           O (y)           O (y)                                                                                                                                      
  Rpn5                                                                                                                           O (y)                                                                                                                                                      
  Rpn6                                 S14 (H, m)                                                 O (H)                          O (y)                                                                                                                                                      
  Rpn7                                                                          O (y)                                                                                                                                                                                                       
  Rpn8                                                                                                                           O (y)                                                                                                                                                      
  Rpn9                                                                                                                                           O (y)                                                                                                                                      
  Rpn11                                                                                                                          O (y)                                                                                                                                                      
  Rpn12                                                                         O (y)             O (H)                                          O (y)                                                                                                                                      
  PA28                                 O (H)                                                                                                                                                                                                                                                
  PI31                                                                                                                                                             O (d)                                                                                                                    
  ------------ ----------------------- --------------------- ------------------ ----------------- ---------------- ------------- --------------- ----------------- --------------- ----------------------- --------------- ------------------ --------------------- ------- ------- ------- ----------

\*Abbreviation, H: human, M: monkey, m: mouse, r: rat, d: drosophila, y: yeast, b: bacteria. ^\#^Same site with human and yeast.

Irreversible PTMs
-----------------

**N-terminal processing:** Five β-subunits (except β3 and β4) of the 20S CP contain N-terminal propeptides that prevent inactivation of the Thr1-containing active site required for proper proteasome assembly via acetylation [@B044]. During assembly of the 20S CP, a conserved Gly-Thr dipeptide within the β1, β2, and β5-subunits is cleaved between the Gly and Thr residues in an autocatalytic fashion to facilitate generation of the active subunit [@B001]. An (evolutionarily conserved) Lys residue located in close proximity to the Gly-Thr cleavage site is also necessary for correct processing of the β subunits [@B001]. Finally, the β6 and β7-subunits are further processed by the neighboring active subunits, whereas β3 and β4 remain unprocessed [@B003].

**Cleavage by caspase:** Several caspases cleave proteasome subunits. For example, during apoptosis, Rpt5, Rpn2, and Rpn10 are cleaved by caspase-3 [@B045], whereas in MCF-7 cells stimulated with the 5-lipoxygenease inhibitor, nordihydroguaiaretic acid, α2, α6, and Rpt1 are cleaved by caspase-7 [@B046]. Cleavage of the above-mentioned subunits by caspse-3 or -7 impairs proteasome activity, resulting in the accumulation of ubiquitinated proteins. However, caspase-3 cleavage of Rpt2 and Rpt6 was shown to increase proteasome activity in staurosporine- or etoposide-treated C2C12 myotubes, although the underlying mechanism has yet to be elucidated [@B047].

**N-myristoylation:** N-myristoylation is a modification in which a myristoyl lipid group is covalently attached to the N-terminal Gly residue of the target protein. MS analyses indicated that Rpt2 contains a highly conserved N-myristoylation motif of at the N-terminus [@B048]. Although the functional consequence of N-myristoylation of Rpt2 is unclear, as myristoylation promotes protein-protein and protein-membrane interactions, the modification is thought to play a role in mediating interactions between the 26S proteasome and membranes or membrane-bound regulatory proteins [@B049].

Reversible PTMs
---------------

**Phosphorylation:** As is the case with many biological processes, proteasome activity is most commonly regulated via phosphorylation of component proteins. Alterations in proteasome subunit conformation resulting from phosphorylation control the stability, assembly, and proteolytic activity of the proteasome. For example, several subunits of the 20S CP are known to be phosphorylated. Phosphorylation of the α-subunit in the *Mycobacterium tuberculosis* proteasome impedes assembly of the proteasome complex and consequently enhances mycobacterial resistance to H~2~O~2~ [@B050]. PKA phosphorylates several subunits of the mammalian 20S CP, including α1-α3, β2, β3 and β7, thus increasing the proteasomal chymotryptic and PGPH activities [@B051]. Phosphorylation of α3 in particular affects the binding of the 19S RP to the 20S CP because the phosphorylated residue is located close to the end of cylinder-shaped 20S CP [@B049]. Under conditions of oxidative stress or ionizing irradiation, the α4-subunit is also phosphorylated on Tyr153 by c-Abl and Arg tyrosine kinase [@B052], ultimately inhibiting proteasomal activity. The c-Abl kinase also phosphorylates the α4-subunit on Tyr 106, in turn promoting the degradation of the α4-subunit via BRCA1-mediated ubiquitination [@B052]. Phosphorylation of the α7-subunit by CKII does not affect proteasomal activity but does stabilize the association between the 19S RP and 20S CP. Bose *et al.* reported that phosphorylation of PA28 is markedly upregulated by INFγ, stimulating the peptidase activity of the proteasome via conformational changes in PA28 [@B053]. Conversely, dephosphorylation of PA28 leads to its dissociation from the 20S CP [@B053].

The ATPase activity of the 19S RP is also regulated by phosphorylation [@B054]. Phosphorylation of the 19S RP also likely affects substrate recognition and gate opening of the 20S CP as well as the assembly of 19S RP subunits due to phosphorylation-induced conformational changes [@B055]. Examples of specific phosphorylation of 19S RP subunits, including targeted residues and the functional consequences and underlying regulatory mechanisms of phosphorylation, have been reported by many investigators, including ourselves. For instance, we demonstrated that under a variety of stressful conditions, the ATPase activity of Rpt5 is inhibited as a result of direct phosphorylation by ASK1 [@B056]. During cell cycle progression, the Rpt3 subunit of the 19S RP is phosphorylated on Thr25 by DYRK2, enhancing substrate translocation to the proteasome complex and subsequent degradation [@B057]. Eventually, it increases tumorigenesis by proteasome-addicted human breast cancer cells in mice [@B057]. Activated PKA phosphorylates Rpn6 on Ser14, whereas both PKA and CaMKII phosphorylate Rpt6 [@B058]. Phosphorylation of Rpt6 by PKA and CaMKII initiates proteasome assembly by enhancing the direct association between Rpt6 and α2 [@B059], [@B060]. In contrast, inhibition of CaMKII prevents the retrieval-induced increase in proteasome activity as well as the phosphorylation of Rpt6 on Ser120 in the amygdala [@B060].

**Ubiquitination and SUMOylation:** Several subunits of 26S proteasome have been identified as targets for conjugation with ubiquitin and small ubiquitin-like modifier (SUMO). Besche *et al.* reported that RING figure E3 ligase Rnf181 attaches mono-ubiquitin to Rpt1 [@B061]. In addition, Rpn10 can be ubiquitinated by three different ubiquitin ligases: RING finger E3 ligase (MuRF1, Siah2, Parkin, SCF^βTRCP1^, and APC), U-box-containing E3 (CHIP), and HECT domain E3 (E6AP and Nedd4) [@B062]. Moreover, the ubiquitin-protein ligase Rsp5 (mammalian homologue Nedd4) catalyzes the Lys63-linked polyubiquitination of Rpn10, whereas Ubp2, a deubiquitinating enzyme, removes the polyubiquitin chain [@B063]. These two enzymes mediate the monoubiquitination of Rpn10 at four Lys residues. Lys84-mono-ubiquitination decreases the ability of Rpn10 to bind polyubiquitinated substrates, consequently inhibiting proteasome activity [@B063]. Mono-ubiquitinated Rpn10 is further modified for Lys48-linked polyubiquitination by the HECT domain E3 enzyme, Hul5. Lys48-linked polyubiquitinated Rpn10 with a Lys84-mono-ubiquitination is then degraded by the 26S proteasome [@B064]. Another ubiquitin receptor, Rpn13, is Lys29- and Lys48-linked polyubiquitinated by 19S RP-associated ubiquitin ligase Hul5 under conditions of proteotoxic stress and reduced proteasomal capacity [@B061]. Ubiquitinated Rpn13 then inhibits the degradation of ubiquitinated proteins (but not peptide substrates) by blocking the binding of the 20S CP to ubiquitin conjugates [@B061]. Furthermore, ubiquitination of the α2-subunit of the 20S CP leads to its interaction with ALAD, a proteasome-associated protein that specifically inhibits endogenous proteasome chymotryptic activity [@B065].

Large-scale proteomics analyses have revealed that similar to ubiquitination, many proteasome subunits undergo SUMOylation, although the functional role of SUMOylation of specific targets remains to be determined. Whereas only four subunits are modified by SUMO-1 in yeast (i.e., Rpn1, Rpn7, Rpn12, and α3), many more proteasome subunits are SUMOylated in human [@B066]. Manza *et al.* identified that several components of the 19S RP and 20S CP are SUMOylated following exposure to oxidative stress. Whereas Rpn10 is modified by SUMO-1, SUMO-3 covalently attaches to the α6-subunit and Rpn10 in the cytosol and to Rpt1 in the nucleus [@B067]. Golebiowski *et al.* reported that eight proteasome subunits (α3, α5, β4, Rpn1, Rpn2, Rpn6, Rpn10, and Rpn12) are conjugated to SUMO-2. Under heat shock treatment, SUMO-2 is conjugated to α5 and β4, and their levels are considerably increased [@B066]. In addition, under conditions of serum starvation, human Rpt1 and Rpt6 are modified by SUMO-4 [@B066].

**N-acetylation:** N-Acetylation of proteasome components occurs via a reversible mechanism mediated by N-acetyltransferase (NAT) and various histone deacetylases (HDACs). For N-terminal acetylation to proceed, the N-terminal methionine must be cleaved before NAT-catalyzed replacement with an acetyl group from acetyl-CoA. There are at least three types of NATs capable of modifying proteasome subunits: NatA (or NAT1), NatB (or NAT3), and NatC (or MAK3). NatA acetylates α1-α4, α7, β3, Rpt4-Rpt6, Rpn2, Rpn3, Rpn5, Rpn6, and Rpn8 [@B068], [@B069], whereas NatB acetylates β4, Rpt3, and Rpn11, and NatC acetylates α5 and α6 [@B068], [@B069]. Acetylation of α-subunits by NatA appears to contribute to gate opening. Non-N-acetylated α-subunits carry a positive charge that induces a conformational change in the 20S CP and gate opening [@B068]. N-Acetylation of the β1-, β2-, and β5-subunits, which form the active site for 20S CP-mediated proteolysis, impedes assembly of the 20S CP [@B044]. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses revealed that human and mouse cardiac proteasome subunits are also acetylated and that acetylation enhances proteasomal capacity under both healthy and diseased conditions [@B070]. In addition, polyubiquitinated α2-subunits are also acetylated in cells treated with an HDAC inhibitor [@B065].

**O-glycosylation:** A number of nuclear and cytoplasmic proteins, including proteasome subunits, are modified with O-linked N-acetylglucosamine, which is attached to the hydroxyl groups on Ser or Thr residue of target proteins, a process known as *O-glycosylation*. Glycosylation of Rpt2 reduces its native ATPase activity and a consequent reduction in proteasome activity [@B071]. Zong *et al.* identified six glycosylated subunits in murine cardiac 20S proteasomes: α1-α3, β2, β5, and β6 [@B072]. Overath *et al.* reported that glycosylated subunits of the 20S proteasome in murine spleen and brain tissues include α1, α4-α6, and β6 [@B073]. To date, glycosylation of only one subunit, α5, has been reported in human erythrocytes [@B074].

**Succinylation:** Lys residues in target proteins can be modified with a succinyl group. LC-MS/MS analyses have identified 13 proteasome subunits that are succinylated in yeast: α3, α4, α7, β3, β4, β6, Rpt3, Rpt6, Rpn2, Rpn3, Rpn9, Rpn12, and Rpn13 [@B075]. The functional consequences of succinylation of any of these subunits remain unknown, however. Interestingly, Weinert *et al.* reported that 10 of the 13 succinylation sites in the yeast subunits are also targets of acetylation, suggesting the possibility of crosstalk between succinylation and acetylation in the proteasome complex [@B075].

**Poly-ADP ribosylation:** Poly-ADP ribosylation involves the addition of one or more ADP-ribose moieties from NAD^＋^ to Glu, Asp, or Lys residues of a substrate, catalyzed by poly (ADP-ribose) polymerase 1 (PARP1). ADP-ribosylation of the nuclear 20S CP by PARP1 increases proteasomal chymotryptic activity and enhances the degradation of damaged histones and oxidized nuclear proteins [@B076]. PI31 is also modified and regulated by ADP-ribosylation, which disrupts the interaction between PI31 and the α-subunits of the 20S CP, upregulating assembly of the 26S proteasome [@B077].

**Oxidation:** Proteasome subunits are sensitive to oxidation by carbonylation, 4-hydroxy-2-nonenal (HNE) modification, and S-glutathionylation. Carbonylation introduces a carbonyl group onto the native amino acid side chains of the target proteins. Rpt3 is carbonylated in response to electrophile-induced oxidative stress, resulting in impaired ATPase activity and subsequently reduced proteasomal activity [@B078]. Divald *et al.* showed that carbonylation of human cardiac Rpt5 subunit increases following ischemia and reperfusion injury [@B079].

Lipid peroxidation by free radicals produced during oxidative stress can lead to HNE modification. The HNE moiety is highly reactive and readily forms covalent linkages to the side chains of Cys, His, and Lys residues in substrate protein via nucleophilic attack. Bulteau *et al.* demonstrated that the tryptic activity of purified myocardial 20S CPs isolated following ischemia and reperfusion injury is dramatically suppressed [@B080]. In addition, coronary occlusion and reperfusion injury results in selective HNE modification of α1-, α2-, and α4-subunits [@B081]. Purified 20S CPs from HNE-treated heart tissue exhibit HNE modification of the α5-, α6-, and β6-subunits [@B081]. In the liver, only α6 is modified as a result of HNE treatment, resulting in inhibition of chymotryptic activity. Based on analyses of 20S CPs purified from HME-treated liver, Farout *et al.* reported that seven proteasome subunits (α2-α5, β3, β4, and β1i) are HNE modified [@B081]. In addition, based on phage display studies using recombinant antibodies, Just *et al.* recently identified an unstable HNE modification on the human α7-subunit [@B082].

*S*-glutathionylation involves the addition of either glutathione (GSH) to cysteine residues or oxidized glutathione (GSSG) to reduced thiol residues, with the resulting formation of mixed disulfides in proteins. The mammalian 20S CP exhibits a biphasic response to *S*-glutathionylation. In the presence of micromolar concentrations of GSH or GSSG, the chymotryptic activity of purified proteasomes increases, whereas in the presence of millimolar GSH or GSSG concentrations, chymotryptic activity declines. An oxidative stress-associated decrease in activity was also reported for *S*-glutathionylated purified yeast 20S CPs [@B083]. *S*-glutathionylation seems to affect 20S CP gate opening. For example, Silva *et al.* identified two *S*-glutathionylated Cys residues in α5-subunits purified from yeast cells [@B084]. Proteasomes in which α5-subunits were *S*-glutathionylated at Cys76 and Cys221 degraded both oxidized and partially unfolded proteins more effectively than proteasomes in which these residues were in the reduced form. Furthermore, Silva *et al.* identified four additional modified residues in α-subunits: α5-Cys117, α6-Cys66, α7-Cys42, and α7-Cys76 [@B084]. *S*-glutathionylation of α5 on Cys76 and Cys221 was shown to produce conformational changes that lead to gate opening in the 20S CP [@B084], [@B085]. In α5-C76S mutant yeast, the gate remains closed, whereas in α5-C221A mutants, the gate was shown to remain open in over 90% of 20S CPs. The 20S CP gate opens to its maximum diameter when α5 Cys76 is *S*-glutathionylated [@B085]. GSH and H~2~O~2~ treatment has also been shown to result in *S*-glutathionylation of 19S RP subunits, including Rpn1 and Rpn2 from neutrophils, HEK293 cells, and purified human 26S proteasomes [@B085]. Analyses of extracts of mouse lung in which catalase has been inactivated also revealed that Rpn1 and Rpn2 are *S*-glutathionylated [@B086].

CORRELATION BETWEEN 26S PROTEASOME DYSFUNCTION AND NEURODEGENERATIVE DISEASES
=============================================================================

The formation of toxic protein aggregates plays an important role in the pathogenesis of many NDs, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD), amyotrophic lateral sclerosis (ALS), and prion disease. The cytotoxicity of these abnormal protein aggregates leads to cell death and concomitant tissue degeneration. Severe impairment of proteasome function in specific areas of brain is observed in many NDs.

AD
--

AD is characterized by progressive memory loss, personality change, and degeneration of language skills. Two characteristic types of protein aggregates are found in the brain of AD patients: senile plaque composed mainly by amyloid beta (Aβ), and neurofibrillary tangle composed of hyperphosphorylated tau protein. Postmortem analyses of brain tissues from AD patients revealed a reduction in proteasome activity in the hippocampus, related limbic structures, and the inferior parietal lobe [@B087]. Aβ inhibits proteasome activity in a dose-dependent manner. Among several processed forms of Aβ identified to date, Aβ40 was shown to inhibit proteasome chymotryptic activity via selective localization inside the active site of the 20S CP; aggregated forms of Aβ42 inhibit proteasome activity by competing with substrates for the active site [@B088]. Hyperphosphorylated tau also inhibits proteasome activity after cross-linking with HNE as well as the ubiquitinated form [@B089]. Tau-associated inhibition of proteasome activity can be attenuated by treatment with PKA activators, which probably act through the phosphorylation of proteasome subunit(s) [@B090].

PD
--

PD patients exhibit both the selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the accumulation of ubiquitinated proteins. Mutations in several genes, including *α-synuclein*, *parkin*, *PINK1*, and *LRRK2*, have been identified in familiar PD patients. As in AD patients, proteasome activity is greatly reduced in the SNpc region of the brain in PD patients. PD patients also exhibit a decline in the levels of 20S CP α-subunits in the brain, PA700, and PA28 [@B091]. Both monomeric and aggregated α-synuclein were shown to inhibit proteasome activity through interaction with the 20S CP [@B092]. Direct binding of parkin to Rpn10 may facilitate transfer of the conjugates to the proteasome [@B093]. Interestingly, parkin also enhances proteasome assembly by enhancing the interactions between non-ATPase and ATPase 19S subunits [@B032]. Various PD-linked mutations in parkin have been shown to abolish the enhancement of proteasome assembly. Decreased activity of both the β5 and β1 proteasome subunits was observed in a mouse model of PD induced by injection of neurotoxin 1-methyl-4-phenylpyridinium into the SNpc area of the midbrain [@B094].

HD
--

HD progression is associated with severe neuronal losses in the thalamus, hippocampus, and spinal cord. In addition, large amounts of aggregated polyubiquitinated huntingtin protein and inclusion bodies are observed in the above-mentioned brain regions. The fibrillary form of huntingtin was shown to inhibit proteasome activity [@B095]. The polyQ sequence interacts with the α-ring of the 20S CP, impeding substrate recognition and binding to the 19S RP [@B096]. Proteasome activity is generally inhibited in brain of HD patients. Jeon *et al.* showed that transfer of the proteasome activator *PA28γ* gene into YAC128 HD mice enhances proteasome activity resulting in improved motor behavior [@B097].

ALS
---

ALS is characterized by the progressive degeneration of motor neurons, leading to muscle weakness. Abnormal protein aggregates are formed due to mutation in Cu, Zn-superoxide dismutase (SOD1). Studies of SOD1^G93A^ transgenic mouse revealed that proteasome activity is inhibited in ALS primarily due to PTM of β5 and decreases in α-subunit levels [@B098].

Prion disease
-------------

The hallmarks of prion diseases are the accumulation of misfolded prion protein (PrP^Sc^) and loss of normal isoform (PrP^c^). Progressive inhibition of proteasome activity results from direct binding of accumulating PrP^Sc^ to the 20S CP, which stabilizes the closed conformation of the gate and prevents substrate entry into the proteasome [@B099]. The onset of proteasome dysfunction is closely correlated with PrP^Sc^ deposition, preceding the earliest behavioral deficits and neuronal loss [@B100].

CONCLUSION AND FUTURE PERSPECTIVE
=================================

In this review, we discussed recent findings regarding the mechanisms that regulate proteasome formation and function, including proteasome assembly, gate opening, and the effects of various PTMs. Over the past 30 years, intensive investigations of the proteasome machinery of organisms ranging from archaea to eukaryotes have greatly enhanced our understanding of the structure and function of these large multi-protein complexes. The complex nature of the structure of proteasomes and the mechanisms regulating their function has been particularly well established in yeast. However, details regarding the specific roles of most mammalian proteasome subunits remain unclear, as does the specific mechanism of substrate unfolding and translocation. We also reviewed current understanding of the putative link between proteasome dysfunction and the occurrence of NDs. Many studies have suggested that changes in proteasome activity are closely associated with a number of NDs. However, whether changes in proteasome activity lead to pathologic increases in protein accumulation or alternatively, whether final aggregate formation leads to proteasome inhibition, remains unclear. In order to fully understand and exploit the potential of the proteasome as a possible therapeutic target, whether (and if so, how) the proteasome coordinates the detoxification and clearance of aggregated proteins must be explored further.

In conclusion, obtaining a complete understanding of the specific mechanisms of proteasome assembly, proteolysis, regulation, and the pathophysiologic correlation between proteasome dysfunction and the occurrence of NDs is critical. Obtaining such an understanding could facilitate the development of therapeutics for treating NDs.
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